RhoA prevents cardiac aging through regulation of mitophagy and NLRP3 inflammasome.
Description: Cardiac aging is associated with structural remodeling and declined cardiac function; hypertrophy, fibrosis, inflammation and decreased contractility. There is a progressive accumulation of damaged mitochondria with age, which is considered to be a major mechanism underlying cardiac aging. Selective elimination of damaged mitochondria by autophagy (mitophagy) plays a central role in preservation of mitochondrial quality. Mitophagy, however, declines with age. Chronic low-grade inflammation is another characteristic of the aging process (inflammaging). The NLRP3 inflammasome is activated in response to various intracellular and extracellular stimuli to produce pro-inflammatory cytokines contributing to a wide range of age-related diseases. Importantly, it has been suggested that mitochondrial dysfunction induces activation of the NLRP3 inflammasome through the release of mitochondrial DNA and reactive oxygen species, but the significance of this interaction in cardiac aging has not been determined. RhoA is a small G-protein that serves as a proximal downstream effector of numerous GPCRs and is also responsive to oxidative stress, providing cardioprotection. The effect of RhoA signaling on cardiac aging has not, however, been determined. The goal of this proposal is to demonstrate that RhoA signaling limits the progression of cardiac aging through preservation of mitochondrial quality by mitophagy and suppression of the NLRP3 inflammasome activity. Aim 1 asks whether RhoA regulates mitophagy to delay the aging process in the heart using cardiac specific RhoA knockout (KO), conditional cardiac specific RhoA deletion and AAV9-mediated RhoA expression in the heart. We will determine whether RhoA stabilizes PINK1 protein through PKD-mediated phosphorylation to induce mitophagy using PINK1 KO and PDK1 KO mice. Aim 2 determines if NLRP3 inflammasome activation in the aging heart is suppressed by RhoA signaling through regulation of mitophagy. We will also determine if RhoA signaling directly inhibits the assembly and activation of the NLRP3 molecular complex. The significance of this research is that it will expand our understanding of the molecular regulation of cardiac aging and dysfunction, providing new targets, regulators of RhoA and its downstream target molecules, with potential therapeutic benefit in treatment of age-related cardiac dysfunction.
Funder: American Heart Association
Amount: $300,000
Funding type: research
Funder scheme: Transformational Project Award
Start date: 2019-07-01
End date: 2022-06-30
Investigator: Shigeki Miyamoto (lead)
Institutions: University of California San Diego, University of California, San Diego
Subfield: Cell Biology
Domain: Life Sciences
Funded outputs count: 8
Funder award ID: 19TPA34910011
OpenAlex ID: G4273457086
